and DUBLIN, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed ...

Amgen has its first direct competition in the KRAS inhibitor class following FDA approval of Mirati's adagrasib as Krazati for a form of lung cancer. Krazati has been cleared as a treatment for ...

Mirati Therapeutics is the subject of takeover speculation in the biopharma sector once again, as it waits for the FDA's decision on its KRAS inhibitor adagrasib in non-small cell lung cancer (NSCLC).

FDMT 4D Molecular Therapeutics, Inc.

Domžale, 8. februarja - Nogometaši Domžal so v 20. krogu Prve lige Telemach izgubili proti Muri z 0:1 (0:1). Celotna novica je dostopna le naročnikom. Novica vsebuje 2.321 znakov (brez presledkov) ...